← The Klinique Med Clinic PCL overview

The Klinique Med Clinic PCL vs H&R Block: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

The Klinique Med Clinic PCL (KLINIQ.BK)

Q3 2026
▲3

KLINIQ raises 2026 target after strong H1, brokers see more upside

  • Company raises 2026 revenue target to 4.5 billion baht KLINIQ lifted its 2026 revenue goal to 4.5 billion baht from 4.15 billion after first-half revenue jumped 33% to 2.21 billion baht and profit rose 33%. Same-store sales grew 21.5%, showing existing clinics are busier, not just new ones. This directly boosts expected earnings and supports a higher share price.

    This is the core new event that resets growth expectations for the year.

  • Brokers raise targets and flag record Q3 profit DAOL and Asia Plus both rate KLINIQ a Buy with targets of 34–35 baht, up from earlier levels. DAOL expects record third-quarter profit of 125–130 million baht and full-year profit up 31% to 476 million baht, driven by 10 new branches and double-digit same-store sales growth. Higher targets pull the share price up.

    Analyst upgrades and record profit forecasts are a direct new catalyst for the stock.

  • Interim dividend of 0.80 baht and high yield attract income buyers KLINIQ is expected to pay an interim dividend of 0.80 baht per share, up 14% from last year, with a full-year yield as high as 5.6%. A steady, rising dividend makes the stock appealing to investors seeking income, which supports demand for the shares.

    Dividend news is a new, concrete return of cash to shareholders that supports the price.

  • Global market jitters make KLINIQ a defensive pick, but risks remain Asia Plus warned of global pressures—oil at $91, rising US bond yields, and a record Thai current-account deficit—and named KLINIQ a safe-haven high-dividend stock. That defensive demand helps, but broad market weakness and foreign selling can still drag the price.

    It shows the main counterweight: KLINIQ benefits as a defensive name but is not immune to market-wide selling.

August 2026
▲3

KLINIQ raises 2026 target after strong H1, brokers see more upside

  • Company raises 2026 revenue target to 4.5 billion baht KLINIQ lifted its 2026 revenue goal to 4.5 billion baht from 4.15 billion after first-half revenue jumped 33% to 2.21 billion baht and profit rose 33%. Same-store sales grew 21.5%, showing existing clinics are busier, not just new ones. This directly boosts expected earnings and supports a higher share price.

    This is the core new event that resets growth expectations for the year.

  • Brokers raise targets and flag record Q3 profit DAOL and Asia Plus both rate KLINIQ a Buy with targets of 34–35 baht, up from earlier levels. DAOL expects record third-quarter profit of 125–130 million baht and full-year profit up 31% to 476 million baht, driven by 10 new branches and double-digit same-store sales growth. Higher targets pull the share price up.

    Analyst upgrades and record profit forecasts are a direct new catalyst for the stock.

  • Interim dividend of 0.80 baht and high yield attract income buyers KLINIQ is expected to pay an interim dividend of 0.80 baht per share, up 14% from last year, with a full-year yield as high as 5.6%. A steady, rising dividend makes the stock appealing to investors seeking income, which supports demand for the shares.

    Dividend news is a new, concrete return of cash to shareholders that supports the price.

  • Global market jitters make KLINIQ a defensive pick, but risks remain Asia Plus warned of global pressures—oil at $91, rising US bond yields, and a record Thai current-account deficit—and named KLINIQ a safe-haven high-dividend stock. That defensive demand helps, but broad market weakness and foreign selling can still drag the price.

    It shows the main counterweight: KLINIQ benefits as a defensive name but is not immune to market-wide selling.

Latest
▲3

KLINIQ raises 2026 target after strong H1, brokers see more upside

  • Company raises 2026 revenue target to 4.5 billion baht KLINIQ lifted its 2026 revenue goal to 4.5 billion baht from 4.15 billion after first-half revenue jumped 33% to 2.21 billion baht and profit rose 33%. Same-store sales grew 21.5%, showing existing clinics are busier, not just new ones. This directly boosts expected earnings and supports a higher share price.

    This is the core new event that resets growth expectations for the year.

  • Brokers raise targets and flag record Q3 profit DAOL and Asia Plus both rate KLINIQ a Buy with targets of 34–35 baht, up from earlier levels. DAOL expects record third-quarter profit of 125–130 million baht and full-year profit up 31% to 476 million baht, driven by 10 new branches and double-digit same-store sales growth. Higher targets pull the share price up.

    Analyst upgrades and record profit forecasts are a direct new catalyst for the stock.

  • Interim dividend of 0.80 baht and high yield attract income buyers KLINIQ is expected to pay an interim dividend of 0.80 baht per share, up 14% from last year, with a full-year yield as high as 5.6%. A steady, rising dividend makes the stock appealing to investors seeking income, which supports demand for the shares.

    Dividend news is a new, concrete return of cash to shareholders that supports the price.

  • Global market jitters make KLINIQ a defensive pick, but risks remain Asia Plus warned of global pressures—oil at $91, rising US bond yields, and a record Thai current-account deficit—and named KLINIQ a safe-haven high-dividend stock. That defensive demand helps, but broad market weakness and foreign selling can still drag the price.

    It shows the main counterweight: KLINIQ benefits as a defensive name but is not immune to market-wide selling.

H&R Block Inc (HRB)

Q3 2026
▲4

H&R Block jumps on record results and strong 2027 guidance

  • Record fiscal 2026 results beat expectations H&R Block reported its best year in five years: revenue rose 4.9% to $3.95 billion and adjusted earnings per share climbed 13.9% to $5.31. The company also gained more clients and kept more of them, which points to a healthier core business and supports a higher stock price.

    This is the core fundamental news that drove the period's move.

  • Fiscal 2027 guidance well above Wall Street estimates Management forecast fiscal 2027 adjusted earnings of $6.04 to $6.24 per share on revenue of $4.11 billion to $4.16 billion, both above analyst consensus. A brighter outlook tells investors the company expects the momentum to continue, which is why the stock jumped 13-16% on the news.

    Guidance is the main new catalyst that re-rated the stock.

  • More cash returned to shareholders H&R Block returned $714 million to shareholders through dividends and buybacks and raised its dividend 10% to $0.46 per share. Returning more cash signals confidence in future profits and makes the stock more attractive to income-focused investors.

    Capital returns are a concrete, new positive for shareholders.

  • New analyst coverage with a $47 target Stephens initiated coverage with an Equal-Weight rating and a $47 price target, and the stock rose 6.2% that day. New analyst attention can bring in fresh investors, though the target was below where the stock later traded, so it is a mild positive rather than a major driver.

    It is a new, separate event that added to early-period gains.

August 2026
▲4

H&R Block jumps on record results and strong 2027 guidance

  • Record fiscal 2026 results beat expectations H&R Block reported its best year in five years: revenue rose 4.9% to $3.95 billion and adjusted earnings per share climbed 13.9% to $5.31. The company also gained more clients and kept more of them, which points to a healthier core business and supports a higher stock price.

    This is the core fundamental news that drove the period's move.

  • Fiscal 2027 guidance well above Wall Street estimates Management forecast fiscal 2027 adjusted earnings of $6.04 to $6.24 per share on revenue of $4.11 billion to $4.16 billion, both above analyst consensus. A brighter outlook tells investors the company expects the momentum to continue, which is why the stock jumped 13-16% on the news.

    Guidance is the main new catalyst that re-rated the stock.

  • More cash returned to shareholders H&R Block returned $714 million to shareholders through dividends and buybacks and raised its dividend 10% to $0.46 per share. Returning more cash signals confidence in future profits and makes the stock more attractive to income-focused investors.

    Capital returns are a concrete, new positive for shareholders.

  • New analyst coverage with a $47 target Stephens initiated coverage with an Equal-Weight rating and a $47 price target, and the stock rose 6.2% that day. New analyst attention can bring in fresh investors, though the target was below where the stock later traded, so it is a mild positive rather than a major driver.

    It is a new, separate event that added to early-period gains.

Latest
▲4

H&R Block jumps on record results and strong 2027 guidance

  • Record fiscal 2026 results beat expectations H&R Block reported its best year in five years: revenue rose 4.9% to $3.95 billion and adjusted earnings per share climbed 13.9% to $5.31. The company also gained more clients and kept more of them, which points to a healthier core business and supports a higher stock price.

    This is the core fundamental news that drove the period's move.

  • Fiscal 2027 guidance well above Wall Street estimates Management forecast fiscal 2027 adjusted earnings of $6.04 to $6.24 per share on revenue of $4.11 billion to $4.16 billion, both above analyst consensus. A brighter outlook tells investors the company expects the momentum to continue, which is why the stock jumped 13-16% on the news.

    Guidance is the main new catalyst that re-rated the stock.

  • More cash returned to shareholders H&R Block returned $714 million to shareholders through dividends and buybacks and raised its dividend 10% to $0.46 per share. Returning more cash signals confidence in future profits and makes the stock more attractive to income-focused investors.

    Capital returns are a concrete, new positive for shareholders.

  • New analyst coverage with a $47 target Stephens initiated coverage with an Equal-Weight rating and a $47 price target, and the stock rose 6.2% that day. New analyst attention can bring in fresh investors, though the target was below where the stock later traded, so it is a mild positive rather than a major driver.

    It is a new, separate event that added to early-period gains.